Among patients with advanced melanoma with disease progression following treatment with anti–PD-1/L1 therapy, relatlimab plus nivolumab (Opdualag) demonstrated early signs of clinical benefit, according to findings from cohort D of the phase 1/2 RELATIVITY-020 trial (NCT01968109) published in the Journal of Clinical Oncology.
2023
High levels of memory killer cells correlate with better survival in melanoma patients
Our skin contains specialized long-lived killer cells that protect against intruders. Researchers at Karolinska Institutet in Sweden and the University of Copenhagen in Denmark have now identified how these cells are formed, and shown that high levels of memory killer cells in cancer tissue correlate with a better survival rate in people with melanoma. The study is published in the journal Immunity.
Advice for Patients Diagnosed with Metastatic Uveal Melanoma
Marlana M. Orloff, MD, offers advice for patients who are diagnosed with metastatic uveal melanoma.
Strategies for Managing Patients With Melanoma
Marc S. Ernstoff, MD, chief for the ImmunoOncology branch of the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis at the National Cancer Institute, provides recommendations for managing patients with metastatic melanoma.